Q3 2025 EPS Estimates for Eli Lilly and Company (NYSE:LLY) Increased by Analyst

Eli Lilly and Company (NYSE:LLY) – Zacks Research lifted their Q3 2025 EPS estimates for Eli Lilly and Company in a note issued to investors on Thursday, October 3rd. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $6.22 for the quarter, up from their prior forecast of $6.21. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $16.49 per share. Zacks Research also issued estimates for Eli Lilly and Company’s Q4 2025 earnings at $7.60 EPS and Q3 2026 earnings at $7.90 EPS.

A number of other equities analysts have also issued reports on LLY. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. BMO Capital Markets raised their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Bank of America upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Finally, Jefferies Financial Group boosted their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Stock Up 1.7 %

Shares of NYSE:LLY opened at $913.72 on Monday. The stock has a market capitalization of $868.40 billion, a price-to-earnings ratio of 134.41, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53. The company’s fifty day moving average is $901.94 and its two-hundred day moving average is $849.30. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%.

Institutional Trading of Eli Lilly and Company

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Lynx Investment Advisory acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at $36,000. Morton Brown Family Wealth LLC boosted its stake in Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after acquiring an additional 15 shares during the last quarter. Unique Wealth Strategies LLC bought a new position in Eli Lilly and Company in the second quarter valued at approximately $45,000. Finally, Redmont Wealth Advisors LLC bought a new position in Eli Lilly and Company during the first quarter worth about $40,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.